A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) ex20ins mutations are rare in NSCLC, associated with poor prognosis and limited treatment options.
• This specific mutation subtype presents unique challenges due to its heterogeneity.
• Existing therapies show limited efficacy against EGFR ex20ins-positive non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To evaluate the efficacy and safety of high-dose furmonertinib as a first-line treatment.
• To assess furmonertinib's impact on patients with EGFR ex20ins-positive NSCLC.
• To determine objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).

Main Methods:

• Retrospective, multi-center, non-interventional study design.
• Enrolled 9 NSCLC patients with EGFR ex20ins mutations from May 2021 to March 2023.
• Evaluated 160 mg furmonertinib, assessing efficacy (ORR, DCR, PFS) and safety (treatment-related adverse events).

Main Results:

• Achieved an objective response rate (ORR) of 66.7% and a disease control rate (DCR) of 88.9%.
• Median progression-free survival (PFS) was 7.2 months.
• No severe (≥ level 3) treatment-related adverse events were observed, indicating a good safety profile.

Conclusions:

• 160 mg furmonertinib demonstrates potential as an effective first-line therapy for advanced NSCLC with EGFR ex20ins mutations.
• The treatment exhibited a favorable safety profile in the studied patient cohort.
• Furmonertinib offers a promising therapeutic option for this challenging subset of NSCLC patients.